Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic

Matthew P Cheng¹, Todd C Lee¹, Darrell H S Tan¹, Srinivas Murthy²

Affiliations

¹ Division of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael's Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC.
² Division of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael's Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC srinivas.murthy@cw.bc.ca.

PMID: 32336678
PMCID: PMC7162442
DOI: 10.1503/cmaj.200438

Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic

Matthew P Cheng et al. CMAJ. 2020.

. 2020 Apr 14;192(15):E405-E407.

doi: 10.1503/cmaj.200438. Epub 2020 Mar 26.

Authors

Matthew P Cheng¹, Todd C Lee¹, Darrell H S Tan¹, Srinivas Murthy²

Affiliations

¹ Division of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael's Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC.
² Division of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael's Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC srinivas.murthy@cw.bc.ca.

PMID: 32336678
PMCID: PMC7162442
DOI: 10.1503/cmaj.200438

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Todd Lee receives salary support from the Fonds de recherche du Québec — Santé. Darrell Tan’s institution has received investigator-initiated research grants or in-kind support from Gilead, Viiv Healthcare and AbbVie. Darrell Tan is a site principal investigator for clinical trials sponsored by GlaxoSmithKline. Darrell Tan is supported by a Tier 2 Canada Research Chair. Srinivas Murthy’s institution has received in-kind support from AbbVie.

Comment in

Sample sizes in COVID-19-related research.
Lee PH. Lee PH. CMAJ. 2020 Apr 27;192(17):E461. doi: 10.1503/cmaj.75308. CMAJ. 2020. PMID: 32392494 Free PMC article. No abstract available.
Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.
Tsang JLY, Binnie A, Farjou G, Fleming D, Khalid M, Duan E. Tsang JLY, et al. CMAJ. 2020 May 19;192(20):E555. doi: 10.1503/cmaj.75585. CMAJ. 2020. PMID: 32575032 Free PMC article. No abstract available.
Excluding pregnancy from COVID-19 trials: Protection from harm or the harm of protection?
Malinowski AK, Snelgrove J, Okun N. Malinowski AK, et al. CMAJ. 2020 Jun 8;192(23):E634. doi: 10.1503/cmaj.75807. CMAJ. 2020. PMID: 32575055 Free PMC article. No abstract available.
Impact of COVID-19 on pediatric clinical research in France.
Flamein F, Gottrand F, Patel ML, Hankard R. Flamein F, et al. CMAJ. 2020 May 25;192(21):E589. doi: 10.1503/cmaj.75416. CMAJ. 2020. PMID: 32575064 Free PMC article. No abstract available.

References

1. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30: 269–71. - PMC - PubMed
1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020. Feb. 18 [Epub ahead of print]. 10.1016/S2213-2600(20)30076-X. - DOI - PMC - PubMed
1. Herrera-Perez D, Haslam A, Crain T, et al. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. eLife 2019;8:e45183. 10.7554/eLife.45183. - DOI - PMC - PubMed
1. Dyer O. What did we learn from Tamiflu? BMJ 2020;368:m626. - PubMed
1. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic

Affiliations

Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic

Authors

Affiliations

Conflict of interest statement

Comment in

References

MeSH terms

LinkOut - more resources

Full Text Sources